TY - JOUR AU - Garcia de Tena, J. PY - 2005 DA - 2005// TI - Inflammation, atherosclerosis, and coronary artery disease JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJM200507283530425 DO - 10.1056/NEJM200507283530425 ID - Garcia de Tena2005 ER - TY - JOUR AU - Ridker, P. M. AU - Hennekens, C. H. AU - Buring, J. E. AU - Rifai, N. PY - 2000 DA - 2000// TI - C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women JO - N Engl J Med VL - 342 UR - https://doi.org/10.1056/NEJM200003233421202 DO - 10.1056/NEJM200003233421202 ID - Ridker2000 ER - TY - JOUR AU - Moutzouri, E. AU - Tsimihodimos, V. AU - Tselepis, A. D. PY - 2013 DA - 2013// TI - Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives JO - Curr Pharm Des VL - 19 UR - https://doi.org/10.2174/13816128113199990307 DO - 10.2174/13816128113199990307 ID - Moutzouri2013 ER - TY - JOUR AU - Macphee, C. H. AU - Nelson, J. AU - Zalewski, A. PY - 2006 DA - 2006// TI - Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target JO - Curr Opin Pharmacol VL - 6 UR - https://doi.org/10.1016/j.coph.2005.11.008 DO - 10.1016/j.coph.2005.11.008 ID - Macphee2006 ER - TY - JOUR AU - Zalewski, A. AU - Macphee, C. PY - 2005 DA - 2005// TI - Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target JO - Arterioscler Thromb Vasc Biol VL - 25 UR - https://doi.org/10.1161/01.ATV.0000160551.21962.a7 DO - 10.1161/01.ATV.0000160551.21962.a7 ID - Zalewski2005 ER - TY - JOUR AU - Tousoulis, D. AU - Papageorgiou, N. AU - Androulakis, E. AU - Stefanadis, C. PY - 2013 DA - 2013// TI - Lp-PLA2--a novel marker of atherosclerosis: to treat or not to treat? JO - Int J Cardiol VL - 165 UR - https://doi.org/10.1016/j.ijcard.2012.09.210 DO - 10.1016/j.ijcard.2012.09.210 ID - Tousoulis2013 ER - TY - JOUR AU - Ballantyne, C. M. AU - Hoogeveen, R. C. AU - Bang, H. AU - Coresh, J. AU - Folsom, A. R. AU - Heiss, G. PY - 2004 DA - 2004// TI - Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study JO - Circulation VL - 109 UR - https://doi.org/10.1161/01.CIR.0000116763.91992.F1 DO - 10.1161/01.CIR.0000116763.91992.F1 ID - Ballantyne2004 ER - TY - JOUR AU - Lind, L. AU - Simon, T. AU - Johansson, L. AU - Kotti, S. AU - Hansen, T. AU - Machecourt, J. AU - Ninio, E. PY - 2012 DA - 2012// TI - Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality JO - Eur Heart J VL - 33 UR - https://doi.org/10.1093/eurheartj/ehs132 DO - 10.1093/eurheartj/ehs132 ID - Lind2012 ER - TY - JOUR AU - Katan, M. AU - Moon, Y. P. AU - Paik, M. C. AU - Wolfert, R. L. AU - Sacco, R. L. AU - Elkind, M. S. PY - 2014 DA - 2014// TI - Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the northern Manhattan study JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0083393 DO - 10.1371/journal.pone.0083393 ID - Katan2014 ER - TY - JOUR AU - Investigators, S. AU - White, H. D. AU - Held, C. AU - Stewart, R. AU - Tarka, E. AU - Brown, R. PY - 2014 DA - 2014// TI - Darapladib for preventing ischemic events in stable coronary heart disease JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1315878 DO - 10.1056/NEJMoa1315878 ID - Investigators2014 ER - TY - JOUR AU - O'Donoghue, M. L. AU - Braunwald, E. AU - White, H. D. AU - Lukas, M. A. AU - Tarka, E. AU - Steg, P. G. PY - 2014 DA - 2014// TI - Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial JO - Jama VL - 312 UR - https://doi.org/10.1001/jama.2014.11061 DO - 10.1001/jama.2014.11061 ID - O'Donoghue2014 ER - TY - JOUR AU - Silber, S. PY - 2019 DA - 2019// TI - ESC guidelines 2019 on chronic coronary syndrome (CCS, previously "stable coronary artery disease") : What is new? What is particularly important? JO - Herz VL - 44 UR - https://doi.org/10.1007/s00059-019-04862-6 DO - 10.1007/s00059-019-04862-6 ID - Silber2019 ER - TY - JOUR AU - Cai, A. AU - Li, G. AU - Chen, J. AU - Li, X. AU - Li, L. AU - Zhou, Y. PY - 2015 DA - 2015// TI - Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population JO - BMC Cardiovasc Disord VL - 15 UR - https://doi.org/10.1186/s12872-015-0001-9 DO - 10.1186/s12872-015-0001-9 ID - Cai2015 ER - TY - JOUR AU - Wilensky, R. L. AU - Macphee, C. H. PY - 2009 DA - 2009// TI - Lipoprotein-associated phospholipase a (2) and atherosclerosis JO - Curr Opin Lipidol VL - 20 UR - https://doi.org/10.1097/MOL.0b013e3283307c16 DO - 10.1097/MOL.0b013e3283307c16 ID - Wilensky2009 ER - TY - JOUR AU - Cai, A. AU - Zheng, D. AU - Qiu, R. AU - Mai, W. AU - Zhou, Y. PY - 2013 DA - 2013// TI - Lipoprotein-associated phospholipase A2 (Lp-PLA (2)): a novel and promising biomarker for cardiovascular risks assessment JO - Dis Markers VL - 34 UR - https://doi.org/10.1155/2013/432136 DO - 10.1155/2013/432136 ID - Cai2013 ER - TY - JOUR AU - Mohler, E. R. AU - Ballantyne, C. M. AU - Davidson, M. H. AU - Hanefeld, M. AU - Ruilope, L. M. PY - 2008 DA - 2008// TI - The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study JO - J Am Coll Cardiol VL - 51 UR - https://doi.org/10.1016/j.jacc.2007.11.079 DO - 10.1016/j.jacc.2007.11.079 ID - Mohler2008 ER - TY - JOUR AU - Daida, H. AU - Iwase, T. AU - Yagi, S. AU - Ando, H. AU - Nakajima, H. PY - 2013 DA - 2013// TI - Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe JO - Circ J VL - 77 UR - https://doi.org/10.1253/circj.CJ-12-0813 DO - 10.1253/circj.CJ-12-0813 ID - Daida2013 ER - TY - JOUR AU - Lp, P. L. A. S. C. AU - Thompson, A. AU - Gao, P. AU - Orfei, L. AU - Watson, S. AU - Angelantonio, E. PY - 2010 DA - 2010// TI - Lipoprotein-associated phospholipase a (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies JO - Lancet VL - 375 UR - https://doi.org/10.1016/S0140-6736(10)60319-4 DO - 10.1016/S0140-6736(10)60319-4 ID - Lp2010 ER - TY - JOUR AU - May, H. T. AU - Horne, B. D. AU - Anderson, J. L. AU - Wolfert, R. L. AU - Muhlestein, J. B. AU - Renlund, D. G. AU - Clarke, J. L. AU - Kolek, M. J. AU - Bair, T. L. AU - Pearson, R. R. PY - 2006 DA - 2006// TI - Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death JO - Am Heart J VL - 152 UR - https://doi.org/10.1016/j.ahj.2006.01.011 DO - 10.1016/j.ahj.2006.01.011 ID - May2006 ER - TY - JOUR AU - Lavi, S. AU - Mcconnell, J. P. AU - Rihal, C. S. AU - Prasad, A. AU - Mathew, V. AU - Lerman, L. O. PY - 2007 DA - 2007// TI - Local production of lipoprotein-associated phospholipase A2 and Lysophosphatidylcholine in the coronary circulation association with early coronary atherosclerosis and endothelial dysfunction in humans JO - Circulation VL - 115 UR - https://doi.org/10.1161/CIRCULATIONAHA.106.671420 DO - 10.1161/CIRCULATIONAHA.106.671420 ID - Lavi2007 ER - TY - JOUR AU - Iwase, M. AU - Sonoki, K. AU - Sasaki, N. AU - Ohdo, S. AU - Higuchi, S. AU - Hattori, H. PY - 2008 DA - 2008// TI - Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment JO - Atherosclerosis VL - 196 UR - https://doi.org/10.1016/j.atherosclerosis.2007.02.012 DO - 10.1016/j.atherosclerosis.2007.02.012 ID - Iwase2008 ER - TY - JOUR AU - Berger, J. S. AU - Ballantyne, C. M. AU - Davidson, M. H. AU - Johnson, J. L. AU - Tarka, E. A. AU - Lawrence, D. PY - 2011 DA - 2011// TI - Peripheral artery disease, biomarkers, and darapladib JO - Am Heart J VL - 161 UR - https://doi.org/10.1016/j.ahj.2011.01.017 DO - 10.1016/j.ahj.2011.01.017 ID - Berger2011 ER - TY - JOUR AU - Buszman, P. PY - 2014 DA - 2014// TI - Darapladib for preventing ischemic events in stable coronary heart disease — NEJM JO - New Eng J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1315878 DO - 10.1056/NEJMoa1315878 ID - Buszman2014 ER - TY - JOUR AU - Blankenberg, S. AU - Stengel, D. AU - Rupprecht, H. J. AU - Bickel, C. AU - Meyer, J. AU - Cambien, F. PY - 2003 DA - 2003// TI - Plasma PAF-acetylhydrolase in patients with coronary artery disease results of a cross-sectional analysis JO - J Lipid Res VL - 44 UR - https://doi.org/10.1194/jlr.M300086-JLR200 DO - 10.1194/jlr.M300086-JLR200 ID - Blankenberg2003 ER -